By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
It´s the first trial to demonstrate the benefits of dual pathway inhibition
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
Subscribe To Our Newsletter & Stay Updated
